OUTSET MEDICAL CAREERS HOW TO

A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference. (the “ Company”) issued a press release and will hold its second quarter 2021 earnings conference call announcing the Company’s financial results for the quarter ended June 30, 2021. Item 2.02 Result of Operations and Financial Condition.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Prior results do not guarantee similar outcomes.Name of each exchange on which registered Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. represents investors and participates in securities litigations involving financial fraud throughout the nation.

OUTSET MEDICAL CAREERS HOW TO

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the OM lawsuit, please contact J. NO COST TO YOU: If you purchased Outset Medical securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Outset Medical you have until Septemto petition the court for lead plaintiff status. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's flagship product, Tablo Hemodialysis System ('Tablo'), would require an additional 510(k) application to be filed with The United States Food and Drug Administration ('FDA'), as defendants had 'continuously made improvements and updates to Tablo over time since its original clearance' (2) as a result, the Company could not conduct a human factors study on a cleared device in accordance with FDA protocols (3) the Company's inability to conduct the human factors study subjected the Company to the likelihood of the FDA imposing a 'shipment hold' and marketing suspension, leaving the Company unable to sell Tablo for home use and (4) as a result, defendants' positive statements about the Company's business, operations, and prospects were materially false and misleading and /or lacked a reasonable basis at all relevant times. Learn more about your recoverable losses in OM:ĬLASS ACTION CASE DETAILS: The filed complaint alleges that Outset Medical, Inc. Lead Plaintiff Deadline: September 6, 2022

This lawsuit is on behalf of all persons or entities who purchased Outset Medical common stock between September 15, 2020, and June 13, 2022. (NASDAQ: OM) alleging that the Company violated federal securities laws. 6, 2022 /PRNewswire/ - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Outset Medical, Inc.

Outset medical careers